Isolate Data
| Patient | Isolate | Region | Year | Species | Subtype | Source | Clone Method |
| CA1422 | CA20051 | U.S. | 2000 | HIV1 | B | Plasma | None |
Treatment History
| Order | Regimen | Weeks |
| 1 | AZT | 29 |
| 2 | None | 14 |
| 3 | AZT | 2 |
| 4 | None | 7 |
| 5 | DDI | 23 |
| 6 | None | 3 |
| 7 | DDI | 4 |
| 8 | AZT+DDC | 6 |
| 9 | DDC | 8 |
| 10 | None | 9 |
| 11 | DDI | 8 |
| 12 | None | 21 |
| 13 | D4T | 4 |
| 14 | None | 23 |
| 15 | D4T | 15 |
| 16 | 3TC+D4T | 37 |
| 17 | 3TC+NVP | 4 |
| 18 | 3TC+D4T | 40 |
| 19 | DDC+NFV+SQV | 27 |
| 20 | EFV+NFV+SQV | 8 |
| 21 | EFV+NFV | 6 |
| 22 | D4T+EFV+NFV | 46 |
| 23 | D4T+NFV+SQV | 12 |
| 24 | APV+D4T+SQV | 10 |
| 25 | ABC+D4T+NVP | 11 |
| 26 | 3TC+ABC+D4T+NVP | 6 |
| 27 | 3TC+AZT+RTV | 3 |
| 28 | None | 19 |
| 29 | 3TC+ABC+D4T | NA |
RT Sequence
| NRTIMajorDRMs | NRTIMinorDRMs | NNRTIMajorDRMs | NNRTIMinorDRMs | Polys | UnusualMuts |
| G190S | E6K, M16MV, V35M, R83RK, K122E, K166R, T200IR, V245E, A272P, K277R | K220KR, V292G |
| >CA20051| codons 1-292 PISPIKTVPVKLKPGVDGPKVKQWPLTEEKIKALMEICTEMEKEGKISKIGPENPYNTPV FAIKKKDSTKWRKLVDFRELNKKTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPL DEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRKQNPDIVI YQYMDDLYVSSDLEIGQHRIKIEELRQHLLRWGFTTPDKRHQKEPPFLWMGYELHPDKWT VQPIELPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTEG |
Protease Sequence
| PIMajorDRMs | PIMinorDRMs | Polys | UnusualMuts |
| I13IV, Q18QE, L63P |
| >CA20490| codons 1-99 PQITLWQRPLVTVKIGGELKEALLDTGADDTVLEEMNLPGRWKPKMIGGIGGFIKVRQYD QIPIEICGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF |
References
| Author | Title | Citation |
| Gonzales, MJ | Extended spectrum of HIV-1 reverse transcriptase mutations in patients receiving multiple nucleoside analog inhibitors. | AIDS, 2003 |
| Gonzales, MJ | Protease and reverse transcriptase mutation patterns in HIV-1 isolates from heavily treated persons: comparison of isolates from northern California with isolates from other regions. | ARHR, 2003 |
| Rhee, SY | HIV-1 Protease and Reverse Transcriptase Mutations: Correlations with Antiretroviral Therapy in Subtype B Isolates and Implications for Drug-Resistance Surveillance. | J Infect Dis, 2005 |